Canada Markets close in 4 hrs

EyeGate Pharmaceuticals, Inc. (EYEG)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.9400+0.0100 (+0.52%)
As of 11:52AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous Close1.9300
Open1.9200
Bid1.9400 x 1400
Ask1.9500 x 1300
Day's Range1.8900 - 1.9600
52 Week Range1.4400 - 8.1800
Volume163,162
Avg. Volume2,001,121
Market Cap13.77M
Beta (5Y Monthly)1.12
PE Ratio (TTM)N/A
EPS (TTM)-1.7680
Earnings DateMar. 25, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est11.83
  • GlobeNewswire

    EyeGate Pharmaceuticals Appoints Eric J. Daniels, MD, MBA, as Chief Development Officer and Closes Acquisition of Bayon Therapeutics, Inc.

    EyeGate adds Bayon Therapeutics’ portfolio of vision-restoring small molecules to its development pipeline Eric J. Daniels, MD, MBA EyeGate Pharma's new Chief Development Officer WALTHAM, Mass., Oct. 26, 2021 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG), (“EyeGate” or the “Company”), a clinical stage specialty pharmaceutical company developing and commercializing products for treating ophthalmic diseases, today announced that it has completed the planned acquisition of Bayon

  • GlobeNewswire

    EyeGate to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

    WALTHAM, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG), (“EyeGate” or the “Company”), a clinical-stage specialty pharmaceutical company developing and commercializing products for treating ophthalmic diseases, today announced that EyeGate’s President and Chief Executive Officer, Brian M. Strem, Ph.D., will provide a corporate update and participate in one-on-one investor meetings at the H.C. Wainwright 23rd Annual Global Investment Conference to be held S

  • GlobeNewswire

    EyeGate Pharma Completes Target Enrollment in Phase 2 Proof-of-Concept Study to Evaluate PP-001 for the Treatment of Ocular Surface Inflammation

    -Proof-of-concept study conducted in Austria; Study designed to build upon positive Phase 1 safety data in healthy volunteers- -Trial remains on track with topline data expected in Q4 2021- WALTHAM, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG), (“EyeGate” or the “Company”), a clinical-stage specialty pharmaceutical company developing and commercializing products for treating ophthalmic diseases, today announced that it has completed target enrollment of